



IPW

Attorney Docket: 2605-1-005N

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): SERAFINI, *et al.*

SERIAL NO.: 10/736,460

EXAMINER: UNASSIGNED

FILED: December 15, 2003

ART UNIT: 1614

TITLE: METHODS FOR USE OF APOPTOTIC CELLS TO DELIVER ANTIGEN TO DENDRITIC CELLS FOR INDUCTION OR TOLERIZATION OF T CELLS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being forwarded by mail in an envelope addressed to The Mail Stop IDS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on October 7, 2005.

Loretta Kavanagh
(Name of Depositor)

Loretta Kavanagh
(Signature and Date)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR § 1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publication forwarded herewith is listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed material, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of the References AA through AY listed on the attached Form PTO-1449. No fee is believe due for the filing of this Statement. However, should the Patent and Trademark Office determine additional fees are due, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

Veronica Mallon
Veronica Mallon, Ph.D.
Agent for Applicant(s)
Registration No. 52,491

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07631
[201] 487-5800



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2605-1-005N
	SERIAL NO.	10/736,460
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	SERAFINI, <i>et al.</i>
	FILING DATE	December 15, 2003
	GROUP	1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA		2,937,204	4/17/60	Harris <i>et al.</i>	564	166	
AB		3,941,783	3/2/76	Grega, <i>et al.</i>	564	166	
AC		5,171,889	12/15/1992	Anderson	564	166	
AD		5,472,983	12/05/1995	Flitter, <i>et al.</i>	514	599	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	AE	1 505 633	3/30/78	GB			
	AF	2,527,113	1/8/76	Germany	564	166	
	AG	2,244,704 A	11/12/1991	GB			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		TITLE: METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME
	AH	Banasik, <i>et al.</i> , "Specific inhibitors of poly (ADP-Ribose) synthetase and mono (ADP-ribosyl) transferase" <i>J. Biol. Chem.</i> (1992) <u>267</u> :1569-1575
	AI	Beal, M.F. in <u>Mitochondrial Dysfunction and Oxidative Damage in Neurodegenerative Diseases</u> , R.G. Landes Publications Austin, TX, (1995) pages 53-61 and 73-99
	AJ	Bishop, <i>et al.</i> "Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)- substituted benzamides: high affinity ligands for CNS dopamine D ₂ receptors" <i>J. Med. Chem.</i> (1991) <u>34</u> : 1612-1624

	AK	Burns, R.S., <i>et al.</i> "A Primate Model of Parkinsonism..." <u>Proc. Natl. Acad. Sci USA</u> (1983) <u>80</u> :4546-4550
	AL	Caine, D.B., "Treatment of Parkinson's Disease" <u>NEJM</u> (Sept. 30, 1993) <u>329</u> :1021-1027
	AM	El Tayar, <i>et al.</i> , "Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure - affinity relationship study" <u>Eur. J. Med. Chem.</u> (1988) <u>23</u> :173-182
	AN	Gerlach, M. <i>et al.</i> , "MPTPMechanisms of Neurotoxicity and the Implications for Parkinson's Disease" <u>European Journal of Pharmacology</u> (1991) <u>208</u> : 273-286
	AO	Heikkila, R.E., <i>et al.</i> , "Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1, 2, 5, 6-Tetrahydropyridine in Mice" <u>Science</u> (June 29, 1984) <u>224</u> : 1451-1453
	AP	Hogberg, <i>et al.</i> , "Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[benzyl-2-pyrrolidinyl]methyl]benzamides. Relations to other side chain congeners" <u>J. Med. Chem.</u> (1991) <u>34</u> :948-955
	AQ	Kato, T., "Reaction of Triethyloxonium Fluoroborate with Acid Amide. III ¹¹) Formation of Quinazoline and 4H-3, 1-Benzoxazin-4-one Derivatives", <u>Chem. Pharm. Bull.</u> (1976) <u>24</u> , 3:431-436
	AR	Katopodis, <i>et al.</i> , "Novel substrates and inhibitors of peptidylglycine α -amidating monooxygenase" <u>Biochemistry</u> (1990) <u>29</u> : 4541-4548
	AS	Langston, J.W., <i>et al.</i> "Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis" <u>Science</u> (February 25, 1983) <u>219</u> , 979-980
	AT	Marsden, C.D., in "Review Article - Parkinson's Disease" <u>Lancet</u> (April 21, 1990) 948-952
	AU	Mizuno, Y., Mori, H., Kondo, T. "Potential of Neuroprotective Therapy in Parkinson's Disease" <u>CNS Drugs</u> (1994) <u>1</u> :45-46
	AV	Monkovic, <i>et al.</i> , "Potential non-dopaminergic gastrointestinal prokinetic agents in the series of substituted benzamides" <u>Eur. J. Med. Chem.</u> (1989) <u>24</u> : 233-240
	AW	Rainnie, <i>et al.</i> , "Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal" <u>Science</u> (1994) <u>263</u> :689-690
	AX	Singer, T.P., <i>et al.</i> , "Biochemical Events in the Development of Parkinsonism..." <u>J. Neurochem.</u> (1987) 1-8
	AY	Patent Abstracts of Japan, vol. 007, no. 155 (C-175), 7 July 1958 & JP, A, 58 067657 (Chugai Seiyaku KK), 22 April 1983, see abstract, see also Derwent abstract 83-52581K
EXAMINER:		DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		